Receptor-based assays.
Recombinant DNA technology has expanded the potential of the targeted screening approach in drug discovery. The use of cloned and expressed receptors as targets for the evaluation of novel compounds can significantly simplify the structure affinity/activity process. However, the patenting of cloned receptors, as well as species differences in receptor pharmacology, especially with respect to human tissues, may limit their use in drug screening. Improved technologies to measure the functional aspects of the receptor-ligand interaction offer the potential to further enhance the targeted screening approach. A greater strategic focus is required to access chemically and biologically diverse ligand sources.